Symbol | Exchange | Currency |
|---|
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today...
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Sell | Strong Sell | Sell |
| Technical Indicators | Buy | Buy | Strong Sell | Strong Sell | Buy |
| Summary | Neutral | Neutral | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.20 | 7.20 | 7.20 | -0.80 | -10.00% | 65.58M | Lagos | |||
| 162.00 | 162.00 | 162.00 | -8.00 | -4.71% | 9.23K | Lagos | |||
| 31.00 | 30.00 | 30.00 | -1.05 | -3.38% | 670.92K | Lagos | |||
| 0.20 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 0.63 | 0.00 | 0.00 | -0.02 | -2.99% | 390.52K | Lagos | |||
| 0.84 | 0.00 | 0.00 | -0.010 | -1.18% | 566.03K | Lagos | |||
| 7.65 | 7.75 | 7.20 | -0.30 | -3.75% | 10.46M | Lagos | |||
| 5.90 | 5.90 | 5.90 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 70.45 | 70.45 | 70.45 | -4.30 | -5.75% | 0.18K | Lagos | |||
| 43.85 | 43.85 | 43.85 | +3.85 | +9.62% | 0.24K | Lagos | |||
| 17.10 | 17.10 | 17.10 | -1.80 | -9.52% | 0.12K | Lagos | |||
| 22.20 | 22.20 | 21.10 | -2.70 | -10.84% | 5.64M | Lagos | |||
| 86.00 | 86.00 | 86.00 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 27.00 | 27.00 | 27.00 | 0.00 | 0.00% | 1.52K | Lagos | |||
| 5.05 | 5.05 | 5.05 | -0.05 | -0.98% | 3.52K | Lagos |
Galecto Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The Company is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.